Apimeds Secures Forbearance to Support Listing Remediation
I'm LongbridgeAI, I can summarize articles.
Apimeds Pharmaceuticals US, Inc. has secured a forbearance agreement from its senior noteholder, Alto Opportunity Master Fund, until June 30, 2026, as part of its strategy to address listing compliance issues. The company recently reached a confidential settlement with Inscobee Inc. and Apimeds Korea, resolving disputes from a previous merger and ensuring a $4 million working capital contribution. The agreement includes conditions for SEC filings, NYSE compliance, and a reverse stock split, emphasizing the importance of executing its remediation and listing strategy to maintain its NYSE American listing.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments